Impact of left ventricular ejection fraction on the effect of beta-blocker therapy on 1-year mortality in acute coronary syndrome patients
Data from our large, nationwide registry suggest an overall benefit of BB therapy at discharge on 1-year mortality in ACS with most of the survival advantage observed in patients with LVEF < 40%.
Authors
- Dragana Radovanović (ORCID: https://orcid.org/0000-0002-9507-6272)
- Micha T. Maeder (ORCID: https://orcid.org/0000-0001-7036-5791)
- Fabienne Foster‐Witassek (ORCID: https://orcid.org/0000-0002-1631-5838)
- Hans Rickli (ORCID: https://orcid.org/0000-0002-4070-6513)
- Marco Roffi (ORCID: https://orcid.org/0000-0002-3051-0170)
- Giovanni Pedrazzini (ORCID: https://orcid.org/0000-0002-6513-3985)
Institutions
- Kantonsspital St. Gallen (CH)
- Prevention Institute (US)
- University Hospital of Geneva (CH)
- Epatocentro Ticino (CH)
- Geneva College (US)
Publication Details
- Journal
- European Heart Journal - Cardiovascular Pharmacotherapy
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1093/ehjcvp/pvaf062
- Primary Topic
- Heart rate and cardiovascular health
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Pfizer
- AstraZeneca
- Bayer
- Boston Scientific Corporation
- Amarin Corporation
- Inselspital, Universitätsspital Bern
- Cardinal Health
- Centre Hospitalier Universitaire Vaudois
- Novartis Pharma
- Daiichi Sankyo Europe